Keywords: Flomax, UK, OTC, Boehringer Ingelheim, USA, Ranbaxy, Generic
UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
Article | 14 December 2009
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has recently approved of the first over-the-counter (OTC) medicine to treat the symptoms of benign prostatic hyperplasia (BPH) in men, to be available through pharmacies without a prescription.
The drug in question, tamsulosin capsules, will be available to buy under the brand name Flomax Relief, for short-term use in men aged 45 to 75 following a consultation with a pharmacist. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
